NEW YORK (GenomeWeb News) – BG Medicine has completed a public offering of 6 million shares of its common stock, raising net proceeds of around $12.8 million.

The Waltham, Mass.-based cardiovascular diagnostics firm said that the underwriters of the offering also exercised their option to purchase 900,000 additional shares. The offering, which was priced at $2 per share, was launched last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.